GlaxoSmithKline Plc (GSK) (NYSE: GSK) announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Nelkarmi (neladalkib), an ALK‑selective tyrosine kinase inhibitor (TKI), for adults with locally advanced or metastatic anaplastic lymphoma kinase (ALK)–positive non‑small cell lung cancer (NSCLC) who have progressed after prior ALK‑directed therapy.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | FDA (United States) |
| Approval Type | Accelerated approval |
| Product | Nelkarmi (neladalkib), oral ALK‑selective TKI |
| Indication | Locally advanced or metastatic ALK‑positive NSCLC in adults after either (i) one prior ALK TKI consisting of alectinib, or (ii) two or more prior ALK TKIs plus platinum‑based chemotherapy in the unresectable locally advanced or metastatic setting |
| Approval Date | 18 Nov 2026 |
| Basis of Approval | Phase I/II ALKOVE‑1 trial |
| Next Steps | Continued approval may be contingent on confirmatory trials demonstrating clinical benefit |
Drug Profile & Mechanism of Action
- Molecule: Neladalkib, a next‑generation ALK‑selective tyrosine kinase inhibitor (TKI) designed to target the ALK fusion protein that drives tumor growth in ALK‑positive NSCLC.
- Targeted Population: Patients who have already exhausted one or more lines of ALK TKI therapy — a setting where acquired resistance mutations limit the durability of existing agents.
- Portfolio Origin: GSK obtained global rights to neladalkib through its acquisition of Nuvalent in June 2026, adding a precision‑oncology asset purpose‑built for the post‑ALK‑TKI resistance landscape.
- Pivotal Program: Evidence stems from the ongoing Phase I/II ALKOVE‑1 trial, which evaluated neladalkib across multiple pretreated cohorts.
Clinical Evidence – Phase I/II ALKOVE‑1 Trial
| Cohort | Confirmed ORR (BICR) | 95% CI | DOR ≥ 6 Months | DOR ≥ 12 Months |
|---|---|---|---|---|
| Alectinib as only prior ALK TKI | 49% (33/67) | 37%–62% | 76% of responders | 52% of responders |
| ≥ 2 prior ALK TKIs + chemotherapy | 32% (50/155) | 24%–40% | 69% of responders | 51% of responders |
Response rates were confirmed by blinded independent central review (BICR). In both heavily pretreated cohorts, the majority of responding patients maintained responses of six months or longer, and roughly half sustained responses beyond twelve months — a notable durability signal in a population with limited remaining options. Additional endpoints, including safety and central nervous system (CNS) activity, were not detailed in the announcement.
Market Impact & Outlook
- Post‑ALK‑TKI Landscape: ALK‑positive NSCLC patients inevitably develop resistance to first‑ and second‑generation ALK TKIs; neladalkib addresses one of the highest‑unmet‑need segments of the disease — treatment beyond alectinib and multi‑TKI failure.
- Strategic Validation: The approval delivers the first US regulatory win for GSK’s Nuvalent acquisition, validating the company’s mid‑2026 bet on next‑generation precision oncology and strengthening its oncology pipeline against established ALK franchise competitors.
- Competitive Positioning: As a mutation‑selective ALK TKI positioned explicitly for pretreated disease, Nelkarmi differentiates from earlier‑line agents and may complement — rather than directly displace — first‑line standards of care.
- Commercial Trajectory: Launch timing, pricing, and any ex‑US regulatory submissions were not disclosed in the announcement; accelerated approval typically requires confirmatory studies to convert to full approval.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, confirmatory trial outcomes, and commercial expectations for Nelkarmi (neladalkib). Actual results may differ materially due to risks including the outcome of post‑marketing confirmatory studies, evolving standards of care in ALK‑positive NSCLC, competitive dynamics, and market adoption. Accelerated approval may be withdrawn if confirmatory trials fail to verify clinical benefit.-Fineline Info & Tech
